QuatRx Pharmaceuticals Announces Positive Phase 3 Results For Study Of Ophena(TM) (ospemifene) To Treat Postmenopausal Vaginal Syndrome
QuatRx Pharmaceuticals Company announced positive results from a pivotal Phase 3 study of Ophena(TM) (ospemifene) to treat postmenopausal women with vulvovaginal atrophy, a common condition associated with menopause. Top line data show that the multi-center, double-blind, placebo-controlled study successfully met all of its co-primary endpoints. The study was conducted in 80 U.S. centers and involved more than 800 women.
More: continued here